NCT01932203

Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 255 (actual)
• Sponsor: Inha University Hospital · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

There may be a difference in efficacy of cilostazol and aspirin on progression of white matter changes in cerebral small vessel disease.

Detailed description

The primary objective of this study is to compare the efficacy of aspirin and cilostazol on volume of white matter changes in cerebral small vessel disease. The secondary objectives are to compare the impact of aspirin and cilostazol on DTI parameters, lacune, microbleeds, brain atrophy, cognition, depression, neurologic signs, gait, urination, and activities of daily living. We also investigate risk factors associated with progression of cerebral small vessel disease.

Conditions

• Cerebral Small Vessel Disease

Interventions

Type	Name	Description
DRUG	aspirin	100mg once a day
DRUG	cilostazol	200mg once a day

Timeline

• Start date: 2013-07-17
• Primary completion: 2019-08-06
• Completion: 2019-08-31
• First posted: 2013-08-30
• Last updated: 2019-08-08

Locations

19 sites across 1 country: South Korea